欧洲脂质体给药市场预测至 2027 年 - COVID-19 影响和按产品进行区域分析（脂质体阿霉素、脂质体紫杉醇、脂质体两性霉素 B 等）；技术（隐形脂质体技术、非聚乙二醇化脂质体技术、DepoFoam脂质体技术）；应用（真菌病、疼痛管理、癌症治疗、病毒疫苗和光动力疗法）和国家
No. of Pages: 124 | Report Code: TIPRE00014191 | Category: Life Sciences
No. of Pages: 124 | Report Code: TIPRE00014191 | Category: Life Sciences
L脂质体是一种新型药物递送系统（NDDS）；是由双层组成的囊泡结构，用于将药物或遗传物质递送到细胞中。 NDDS 旨在在治疗期间按照身体需要的速率提供药物。因此，脂质体药物输送市场的公司利用这个机会加强对纳米材料（如纳米球、脂质体和活性抗病毒药物）的研究。脂质体药物递送正在利用增加的体内和体外药物活性进行常规临床实践。
2019年欧洲脂质体给药市场价值为116454万美元，预计到2027年将达到216012万美元；预计在预测期内复合年增长率为 8.2%。 药物输送的研发支出不断增长，对非侵入性药物输送装置的需求不断增长，以及开发新的脂质组合物以实现稳定性和优化药物是脂质体药物输送市场的关键驱动力。然而，高昂的研发成本和COVID-19大流行可能会对市场增长产生负面影响。
< p>
基于产品，l脂质体阿霉素细分市场在2019年欧洲脂质体给药市场中占有最高份额，而脂质体两性霉素B细分市场预计在预测期内将以最快的速度增长。从技术来看，隐形脂质体技术占据了最大的市场份额，预计在预测期内将以最快的速度增长。根据应用情况，癌症治疗细分市场在2019年占据欧洲脂质体给药市场的最大份额，并且预计在预测期内以最快的速度增长。
报告中包括欧洲脂质体药物输送市场的一些主要主要和次要来源是新型药物输送系统(NDDS)、Celsion Corporation、欧洲和发展中国家临床试验合作伙伴关系(EDCTP)、EuropaBio、欧洲生物技术联合会(EFB)。 >
< /p>
欧洲脂质体药物输送市场 -按产品
· 脂质体阿霉素
· 脂质体紫杉醇
· 脂质体两性霉素B
· 其他
; ;
欧洲脂质体药物输送市场 -通过技术
· 隐形脂质体技术
· 非聚乙二醇化脂质体技术
· ; DepoFoam脂质体技术
· 溶脂热敏脂质体（LTSL）技术
欧洲脂质体药物输送市场——通过申请
· 真菌病
· 癌症治疗
· 疼痛管理
· 病毒疫苗
· 光动力疗法
Strategic insights for Europe Liposome Drug Delivery involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 1,164.54 Million |
| Market Size by 2027 | US$ 2,160.12 Million |
| Global CAGR (2019 - 2027) | 8.2% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 产品
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Liposome Drug Delivery refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Liposome Drug Delivery Market is valued at US$ 1,164.54 Million in 2019, it is projected to reach US$ 2,160.12 Million by 2027.
As per our report Europe Liposome Drug Delivery Market, the market size is valued at US$ 1,164.54 Million in 2019, projecting it to reach US$ 2,160.12 Million by 2027. This translates to a CAGR of approximately 8.2% during the forecast period.
The Europe Liposome Drug Delivery Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Liposome Drug Delivery Market report:
The Europe Liposome Drug Delivery Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Liposome Drug Delivery Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Liposome Drug Delivery Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Liposome Drug Delivery Market
